PSA (prostate-specific antigen) is a blood marker produced by prostate tissue. A high PSA does not automatically mean prostate cancer: benign prostate enlargement, prostatitis, urinary retention and recent prostate manipulation can also raise it. There is no single PSA number that separates cancer from non-cancer. Interpretation depends on age, prostate volume, previous PSA trend, digital rectal examination, family/genetic risk and, increasingly, prostate MRI and PSA density. In an asymptomatic man with a moderately elevated result, repeating PSA under standardised conditions is often appropriate before moving directly to biopsy.

What does PSA actually measure?

PSA is made by both normal and abnormal prostate cells. Cancer can increase the amount reaching the bloodstream, but benign enlargement can do the same simply because there is more prostate tissue. PSA is therefore prostate-specific rather than cancer-specific.

Reasons PSA may be temporarily high

• Urinary infection or acute prostatitis.
• Acute urinary retention.
• Recent catheterisation or instrumentation in some settings.
• Ejaculation or vigorous cycling may produce small short-lived changes in some men.
• Recent prostate biopsy or surgery.
• Large benign prostate volume.

Why repeating PSA can matter

EAU guidance notes that PSA can vary meaningfully between measurements. For asymptomatic men with an initial PSA in the moderately elevated range, a repeat test after several weeks under similar conditions can prevent unnecessary investigation when the value normalises. Infection or acute urinary retention should be addressed first before interpreting a transiently high result.

PSA density

PSA density (PSAD) is total PSA divided by prostate volume in mL/cc, usually measured on MRI or ultrasound. A higher PSAD increases suspicion that the PSA is not explained by benign prostate size alone. It is used with MRI findings and other risk factors rather than as an independent yes/no test.

PSA velocity and trend

A rising trend can be relevant, but short-term fluctuations are common. PSA velocity alone should not be used as the sole reason for biopsy. The pattern becomes more useful when measurements are comparable and there is a clear long-term change.

What may happen after a persistently elevated PSA?

The urologist may perform a digital rectal examination, review prostate size, calculate PSA density and request multiparametric MRI. If MRI or overall risk is suspicious, targeted and systematic/perilesional biopsy may be discussed. A low-risk MRI does not make cancer impossible, so PSAD, family history and other factors still matter.

Medicines that affect PSA

5-alpha-reductase inhibitors such as finasteride or dutasteride lower PSA over time, often by roughly half after sustained use. The treating doctor must know if you take them because the measured value requires contextual interpretation. Testosterone therapy can also change monitoring needs.

When to see a urologist promptly

• Persistently rising or clearly elevated PSA after repeat testing.
• Abnormal digital rectal examination.
• Visible blood in urine, bone pain or major unexplained weight loss with prostate concerns.
• Strong family history, BRCA2 or another high-risk genetic background.
• PSA elevation together with urinary infection/retention requiring treatment.

How to prepare for a repeat PSA

If PSA is being repeated after an unexpected elevation, try to use the same laboratory when practical and avoid testing during an active urinary infection or immediately after acute retention or major prostate instrumentation. Tell the doctor about recent catheterisation, biopsy, prostate surgery and all prostate medicines. Standardising conditions reduces noise in the trend.

Age-specific PSA ranges can be helpful but are not absolute safety limits. Modern decisions increasingly use multivariable risk: PSA density, MRI, examination, family/genetic risk and prior biopsy history. A number just below a laboratory cutoff should not be automatically labelled safe if the rest of the picture is concerning.

How PSA, MRI and PSA density fit together

A PSA result is strongest when it is placed into a risk model rather than treated as a pass/fail number. Current EAU guidance recommends repeating PSA before further investigation in many asymptomatic men with an initial PSA of 3-10 ng/mL, and using prostate MRI, a calibrated risk calculator or selected biomarkers to decide who needs biopsy.

PSA density is PSA divided by prostate volume. A density around or above 0.15 ng/mL/cc has historically increased concern, but modern MRI pathways use it as a continuum rather than a rigid cutoff. For example, a negative MRI with very low PSA density is more reassuring than the same negative MRI with a high PSA density.

What a urologist usually wants before calling PSA ‘persistently elevated’

A repeat PSA is most useful when obvious transient factors have settled and the laboratory method is comparable. The clinician will also want prostate volume, digital rectal examination findings, family history, previous PSA values and whether the patient is taking finasteride or dutasteride. These drugs can substantially lower measured PSA, so the raw number needs contextual interpretation.

If risk remains meaningful after repeat testing, MRI is not just another screening blood test—it localises suspicious lesions, estimates prostate volume for PSA density and helps target biopsy. A biopsy decision is strongest when PSA, MRI and clinical risk point in the same direction rather than when one borderline value dominates the discussion.

What to bring for consultation

• All previous PSA values with dates.
• Prostate ultrasound/MRI reports and images.
• Urine culture if infection was suspected.
• List of prostate medicines, especially finasteride/dutasteride.
• Family history of prostate, breast, ovarian or pancreatic cancers if relevant.

FAQs

Related reading

• Free PSA vs Total PSA Report Explained
• Prostate MRI Report Explained
• PI-RADS Score on MRI Explained
• Prostate Enlargement on Ultrasound
• HPE / Biopsy Report Explained
• Urologist in Latur

References

• European Association of Urology. EAU Guidelines on Prostate Cancer: Diagnostic Evaluation. 2026 https://uroweb.org/guidelines/prostate-cancer/chapter/diagnostic-evaluation